Detalhe da pesquisa
1.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641218
2.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet
; 394(10212): 1915-1928, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31679945
3.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718784
4.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866947
5.
18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
BMC Cancer
; 18(1): 548, 2018 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743108
6.
Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.
J Oral Maxillofac Surg
; 76(4): 775-784, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29035698
7.
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Strahlenther Onkol
; 192(8): 526-36, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27306747
8.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
BMC Cancer
; 16(1): 780, 2016 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27724870
9.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
J Clin Oncol
; 41(4): 790-802, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36219809
10.
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
J Clin Oncol
; 40(21): 2321-2332, 2022 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35333599
11.
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Oral Oncol
; 128: 105815, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35381576
12.
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Neoplasia
; 23(5): 473-487, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878706
13.
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
J Clin Invest
; 130(3): 1417-1430, 2020 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31805013
14.
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
Radiother Oncol
; 150: 62-69, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32540337
15.
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease.
Oncotarget
; 10(62): 6647-6650, 2019 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31803359
16.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Oral Oncol
; 81: 45-51, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884413
17.
Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Oncotarget
; 7(46): 76151-76158, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27764819
18.
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Breast
; 23(5): 511-25, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24986766
19.
Late term tolerance in head neck cancer patients irradiated in the IMRT era.
Radiat Oncol
; 8: 259, 2013 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24192223
20.
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
Wien Klin Wochenschr
; 125(15-16): 439-47, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23832237